Growth Hormone Deficiency Segmentation
Product (Recombinant Human Growth Hormone, Biosimilars)
Based on product, the recombinant human growth hormone segment is expected to garner the highest share of 58.5% in the growth hormone deficiency market by the end of 2037. The dominance of the segment is possible due to the increased efficacy as approved by the FDA and EMA, and favorable reimbursement policies in the U.S and EU. Besides WHO reports that intensifying competition between biosimilar firms is anticipated to reduce prices by more than 15% thereby increasing access to recombinant growth hormones.
Application (Pediatric GHD, Adult GHD, Turner Syndrome, Prader-Willi Syndrome)
Based on application, the pediatric GHD segment is projected to account for a lucrative share of 47.3% in the growth hormone deficiency market during the forecast period. The segment witnesses such growth due to the safety measures imposed across all nations. In this regard CDC reports that more than 30 countries across the world are mandating neonatal screenings, which drives growth in the pediatric growth hormone deficiency segment. Besides, NIH states that the extensive adoption of telemedicine in remote areas is improving 18% diagnostic rates annually, further fostering expansion of the segment.
Our in-depth analysis of the growth hormone deficiency market includes the following segments:
|
Product |
|
|
Application |
|
|
Distribution Channel |
|
